mRNA skin cancer treatment shows promise: drug makers

Moderna and Merck report positive early Phase 3 trial results for an individualized mRNA melanoma vaccine. The treatment, used alongside immunotherapy, aims to prevent cancer recurrence and spread by training the immune system to identify and destroy remaining cancer cells. While share prices surged, full data is pending publication this fall.